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Background: The use of midazolam for dental care in patients with intellectual disability is poorly documented. 
The purpose of this study was to determine which method of premedication is more effective for these patients, 
0.15 mg/kg of intramuscular midazolam or 0.3 mg/kg of oral midazolam.
Material and Methods: This study was designed and implemented as a non-randomized retrospective study. The 
study population was composed of patients with intellectual disability who required dental treatment under am-
bulatory general anesthesia from August 2009 through April 2013. Patients were administered 0.15 mg/kg of 
midazolam intramuscularly (Group IM) or 0.3 mg/kg orally (Group PO). The predictor variable was the method 
of midazolam administration. The outcome variables measured were Observer’s Assessment of Alertness/ Seda-
tion (OAA/S) Scale scores, the level of cooperation when entering the operation room and for venous cannulation, 
post-anesthetic agitation and recovery time.
Results: Midazolam was administered intramuscularly in 23 patients and orally in 21 patients. More patients 
were successfully sedated with no resistance behavior during venous cannulation in Group PO than in Group IM 
(p=0.034). There were no differences in demographic data and other variables between the groups.
Conclusions: The results of this study suggest that oral premedication with 0.3 mg/kg of midazolam is more ef-
fective than 0.15 mg/kg of midazolam administered intramuscularly, in terms of patient resistance to venous can-
nulation. If both oral and intramuscular routes of midazolam are acceptable in intellectually disabled patients, the 
oral route is recommended.
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The number of people with special needs who require 
oral health services is increasing (1). Patients with spe-
cial needs, such as those with intellectual disability, 
are sometimes uncooperative for medical procedures, 
especially dental procedures. For such patients, general 
anesthesia is a useful method that enables completion 
of dental treatment. When general anesthesia is applied 
to intellectually disabled dental patients, sedation by 
premedication is essential to reduce induction anxiety. 
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Since general anesthesia for such patients is usually giv-
en in an ambulatory setting in which rapid recovery is 
required, the route of administration of the premedicant 
is important.
Although several drugs, such as ketamine (2), clonidine 
(3) and dexmedetomidine (4,5), are used as sedative 
premedication in pediatric patients, midazolam is one 
of the most popular sedatives. However, little is known 
about the ideal dose or route of administration of mi-
dazolam for intellectually disabled patients undergoing 
ambulatory surgery. We performed this study to com-
pare the effects of oral versus intramuscular midazolam 
as premedication before dental surgery under general 
anesthesia in intellectually disabled subjects. This study 
was designed as a non-randomized retrospective study 
because most patients and their parents or caregivers 
preferred the oral route for administration of the pre-
medicant, and hence, the patients could not be randomly 
allocated to the two groups.
Material and Methods
To address the research purpose, the investigators de-
signed and implemented a retrospective study to eva-
luate the effectiveness of intramuscular and oral admin-
istration of midazolam as sedative premedication before 
general anesthesia in intellectually disabled patients. 
This study was performed according to the Declaration 
of Helsinki and approved by the institutional review 
board and ethics committee of Osaka University Dental 
Hospital (H26-E50).
- Patients
The study population was composed of patients with in-
tellectual disability receiving dental treatment under am-
bulatory general anesthesia from August 2009 through 
April 2013. To be included in the study, patients had to 
be American Society of Anesthesiologists Physical Sta-
tus (ASA-PS) class I or II, and aged over 16 years old. 
Patients were excluded from participation if their body 
weight was over 67 kg, because the oral dose of mida-
zolam was limited to a maximum of 20 mg in this study. 
Patients who could not walk normally, declined measure-
ment of their BP, or whose perioperative records were 
incomplete, were also excluded. All study variables were 
collected from the medical or anesthesia records.
- Standard ambulatory anesthesia procedure
Patients were admitted to the hospital by 8:30 a.m. after 
more than 8 hours of fasting. If patients regularly took a 
morning dose of tranquillizers or anti-epilepsy medica-
tion, they were asked to take these drugs between 6:00 
and 7:00 a.m. with a little plain water. After entering 
the day surgery preparation room, patients were admin-
istered midazolam (Dormicum, Astellas, Tokyo, Japan) 
intramuscularly (0.15 mg/kg: Group IM) or orally (0.3 
mg/kg: Group PO) as premedication. Orally adminis-
tered midazolam was limited to a maximum dose of 20 
mg (6). The oral premedication syrup was prepared by 
mixing midazolam in a sucrose based syrup (Simple 
syrup, Mylan, Tokyo, Japan). The administration route 
was determined according to the parent’s request and 
patient’s acceptance on the day of preoperative exami-
nation.
Patients’ sedation level was evaluated by the dental an-
esthesiologist approximately 15 and 30 min after pre-
medication in Group IM and Group PO, respectively, 
using the Observer’s Assessment of Alertness/Sedation 
(OAA/S) scale (7). OAA/S scale scores are rated as fol-
lows: 5, awake and responds readily to name spoken 
in a normal tone; 4, lethargic response to name being 
called in a normal tone; 3, responds only after name is 
called loudly or repeatedly (or both); 2, responds only 
after name is called loudly and after mild shaking; and 
1, does not respond despite name being called and being 
mildly shaken.
After evaluation of the sedation level, the patients en-
tered the operation room from the day surgery prepara-
tion room and lay down on the operating table. Then, a 
peripheral 22-gauge catheter was inserted into a dorsal 
hand vein. Patient cooperativeness during transfer and 
during venous cannulation was closely recorded. The 
patient’s condition during transfer and when entering 
the operation room was eva luated by an original score: 
1, sleeping; 2, cooperative; 3, fighting. The patient’s 
condition during venipuncture was also evaluated as: 1, 
no body movement; 2, cooperative; 3, fighting.
Anesthesia was usually induced with 5 mg/kg of thiamy-
lal sodium (Isozol, Nichi-Iko Pharma Tech Co., Toyama, 
Japan), followed by 0.6 mg/kg of rocuronium bromide 
(Eslax, MSD K. K., Tokyo, Japan) to facilitate nasotra-
cheal intubation. After intubation, a nasogastric tube was 
inserted to withdraw gastric contents. Anesthesia was 
maintained with 66% nitrous oxide and sevoflurane at 
an end-tidal concentration of 1 to 2% in oxygen (Fabius 
Tiro, Dräger Medical Inc., Lübeck, Germany).
When the procedure was expected to be painful, 2% 
lidocaine with 1:80,000 epinephrine was injected for 
local anesthesia. When the patient underwent tooth ex-
traction, 1 mg/kg of flurbiprofen axetil (Ropion, Kaken 
Pharmaceutical Co. Ltd., Tokyo, Japan), up to a dose of 
50 mg, was administered intravenously before the end 
of the operation.
Immediately after the end of the dental procedure, ad-
ministration of sevoflurane was discontinued. After ex-
tubation, agitation score was evaluated according to the 
scoring system for emergence delirium as (8): 1, sleep-
ing; 2, awake, calm; 3, irritable, crying; 4, inconsolable 
crying; 5, severe restlessness, disorientation.
Thereafter, patients were shifted from the operating 
room to the post anesthesia care unit (PACU). Blood 
pressure, pulse rate, arterial oxygen saturation (SpO2), 
body temperature, and modified post anesthetic dis-
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charge scoring system (mPADSS) scores (9,10) were 
measured and evaluated every 30 or 60 min until dis-
charge. Recovery time was defined as the time from 
extubation until the patients obtained a mPADSS score 
≥ 9. Actual discharge was permitted when the patients 
satisfied the mPADSS score ≥ 9 criterion and after con-
firmation of the ability to drink fluids and adequate 
urine output while in the PACU.
- Statistical analyses
In this study, the primary predictor variable was the ad-
ministration method of midazolam. The outcome vari-
ables measured were OAA/S Scale score, transfer con-
dition while entering the operation room, venipuncture 
condition, post-anesthetic agitation and recovery time. 
The third category of variables studied included gender, 
age, height, weight, anesthesia time, operation time and 
coexisting disabilities.
Distributions of patients’ values were tested for nor-
mality using the Shapiro-Wilk test. Since distribution 
of anesthesia time and operation time were non-normal 
(P < 0.05), the Mann-Whitney test was used for analy-
sis. These data are expressed as median (interquartile 
range). Parameters with normal distributions (P > 0.05) 
and equal variance (P > 0.05), such as age, height, body 
weight and recovery time, were analyzed by the Levene 
and unpaired t tests. These data are expressed as mean 
± standard deviation. Patient gender, medications, co-
existing disabilities, OAA/S scale score, transfer condi-
tion, venipuncture condition and agitation score were 
compared by the chi-square test. Statistical analysis was 
performed with the SPSS software package (SPSS ver-
sion 22.0; IBM Corp., Armonk, NY, USA). A P value 
less than 0.05 was considered statistically significant.
Results
Anesthesia records of 159 patients were reviewed and a 
total of 44 patients were finally analyzed. Twenty-three 
patients were administered midazolam intramuscular-
ly and 21 orally (Fig. 1). Table 1 presents the clinical 
characteristics and procedural summary of all patients. 
!
Assessed for eligibility (n=292) 
Excluded  (n=133) 
!!!!Age < 16 Y (n=60) 
!!!!Body weight > 67 kg (n=71) 
!!!!Other reasons (n=2) 
 
Analyzed (n=23) 
Intramuscular administration (n=87) 
!!Did not ultimately receive midazolam 
intramuscularly (n=0)!
Oral administration (n=72) 
!!Did not receive oral midazolam (n= 5). Patients 
declined oral administration, hence 




Evaluated for administration route of midazolam (n=159) 
Received midazolam intramuscularly (n=87)!
!!Excluded from analysis (n=64) 
Incomplete perioperative record 
Patients declined measurement of BP  
Patients could not walk normally 
 
Received oral midazolam (n=67) 
!!Excluded from analysis (n=46) 
Incomplete perioperative record 
Patients declined measurement of BP  
Patients could not walk normally 
 
Fig. 1. Flow diagram demonstrating patient inclusion in the study.
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There were no significant differences in age, gender, 
height, body weight, medications such as tranquilizers 
and anticonvulsant drugs, anesthesia time, operation 
time and recovery time between the two groups. There 
were also no significant differences in the number of 
patients with and without mental retardation, autism, 
cerebral palsy and epilepsy.
The sedation level after premedication is shown in ta-
ble 2. An OAA/S score of 4 was most frequent in both 
groups, while some patients were deeply sedated. How-
ever, there were no significant differences in the seda-
tion level after premedication between the two groups.
The patients’ condition at the time of transfer to the 
operating room is shown in table 3. Over 90% of the 
patients (41/44) were transferred to the operating room 
without any resistant behaviors. There were no signifi-
cant differences in transfer condition scores between 
the two groups. The condition of the patients at the time 
of intravenous cannulation is also shown in table 3. The 
score of cannulation condition was significantly lower in 
Group PO than in Group IM (p=0.034). More patients 
in Group PO were more deeply sedated than patients in 
Group IM during venous cannulation. However, 3 pa-
tients exhibited resistant behaviors in each group.
Agitation scores after extubation are shown in table 4. 
There were no significant differences in the score of 
transfer condition and agitation after extubation be-




Gender (M/F) 16/7 16/5 0.622
Age (y) 28.9±10.9 27.3±8.2 0.604
Height (cm) 163.2±10.2 165.9±7.8 0.336
Body weight (kg) 52.1±9.4 56.6±6.9 0.078
Mental retardation (Y/N) 23/0 21/0 -
Autism (Y/N) 10/13 13/8 0.222
Cerebral Palsy (Y/N) 2/21 0/21 0.267
Epilepsy (Y/N) 19/4 19/2 0.378
Medications (Y/N) 15/8 14/7 0.919
Anesthesia time (min) 175 (156-190) 175 (146-194) 0.888
Operation time (min) 126 (102-137.5) 131 (114-142) 0.526
Recovery time (min) 126.2±65.5 100.1±61.0 0.179
Table 1. Patients’ clinical characteristics and procedural summary.
IM, intramuscular premedication; PO, oral premedication










Table 2. Observer’s Assessment of Alertness/Sedation 
(OAA/S) scale scores after administration of midazolam.
IM, intramuscular premedication; PO, oral premedication
OAA/S scale scores indicate the following: 5, awake and re-
sponds readily to name spoken in a normal tone; 4, lethargic 
response to name being called in a normal tone; 3, responds 
only after name is called loudly or repeatedly (or both); 2, re-
sponds only after name is called loudly and after mild shak-
ing; and 1, does not respond despite name being called and 
















Table 3. Patients’ condition at the time of transfer in to the op-
eration room and intravenous cannulation.
IM, intramuscular premedication; PO, oral premedication
Transfer condition was scored as follows: 1, sleeping; 2, co-
operative; 3, fighting. Data represent number of patients. The 
patients’ condition at the time of intravenous cannulation was 
defined as follows: 1, no body movement; 2, cooperative; 3, 
fighting. Data represent number of patients. 
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Discussion
The main finding of this study was that 0.3 mg/kg of oral 
midazolam was more effective in facilitating intravenous 
cannulation than 0.15 mg/kg of intramuscular midazo-
lam. Although there were no differences in OAA/S scale 
scores after sedation and in the post-anesthesia transfer 
condition between the two groups, 0.3 mg/kg of oral mi-
dazolam could reduce venipuncture-related anxiety.
The optimal intramuscular and oral dose of midazolam 
for patients with intellectual disability is not known. In 
normal adult patients, the optimal premedication dose 
of intramuscular midazolam was reported to be 0.08 
mg/kg (11). However, based on our clinical experience, 
we believe that a larger dose is required in patients with 
intellectual disability. On the other hand, in pediatric 
patients, 0.5 mg/kg of oral midazolam reportedly pro-
vides effective sedation when it is used as premedica-
tion before general anesthesia (12). However, it seems 
inappropriate to use the same dose for uncooperative 
pediatric patients and for adult patients with intellectual 
disability. If 0.5 mg/kg of midazolam is given orally to 
adult patients, it is perfectly possible that side effects 
such as delayed recovery due to over dosage may oc-
cur. This complication should be avoided, especially in 
ambulatory anesthesia.
There are a few studies on oral midazolam premedica-
tion for intellectually disabled patients. Maeda et al. 
used a small dose of oral midazolam (an average of 
0.042 mg/kg) before induction of general anesthesia 
when intravenous cannulation was difficult (13). They 
reported the usefulness of midazolam premedication to 
reduce fear. However, the same group also reported that 
0.3-0.5 mg/kg of oral midazolam before induction of se-
dation provided adequate sedation (14). The reason for 
the difference in the dose of midazolam between gen-
eral anesthesia and sedation was unmentioned. Collado 
et al. used 0.3 to 0.5 mg/kg of oral midazolam and if 
necessary, additional inhalation sedation (50% nitrous 
oxide/oxygen), and demonstrated the improvement in 
patient cooperation (modified Venham scale 0-3) during 
venous cannulation in about three-quarters of patients 
(15). Asahi et al. gave 0.3 mg/kg of oral midazolam to 
combative patients (16).
Therefore, the dose of oral midazolam was determined 
to be 0.3 mg/kg and a maximum dose of up to 20 mg (6) 
was used in the present study. The dose of intramuscu-
lar midazolam was determined to be 0.15 mg/kg (6,17), 
because 50% of orally administered midazolam reaches 
the systemic circulation due to the hepatic first-pass ef-
fect (18).
Midazolam premedication has an 86% success rate in 
terms of improvement in intravenous cannulation condi-
tions (38/44: Cannulation condition score 2 or 3/ Group 
IM and PO). The proportion of patients with a cannu-
lation score of 3 was 61.9% (13/21) in Group PO and 
26.1% (6/23) in Group IM. Our results suggest that 0.3 
mg/kg of oral midazolam provides adequate sedation 
during intravenous cannulation. In the present study, 
there was no difference in recovery times between the 
groups. The effect of oral midazolam on recovery time 
is still controversial.
In pediatric patients, Bevan et al. (19) showed prolonged 
recovery after oral premedication with midazolam 0.5 
mg/kg, and Mishra et al. (20) reported delayed recovery 
associated with high dose oral midazolam administra-
tion (1.0 mg/kg). However, Horgesheimer et al. reported 
that 0.5 mg/kg of oral midazolam premedication did not 
delay discharge of children undergoing general anes-
thesia for dental treatment (21). The systematic review 
from Cox et al. also demonstrated that premedication 
with oral midazolam 0.5 mg/kg has minimal effect on 
recovery time (12).
Maeda et al. demonstrated that oral midazolam was 
associated with delayed recovery after dental sedation 
(14) and ambulatory general anesthesia (13). However, 
their mean treatment time was shorter (43.1 min under 
sedation and 88.0 min under general anesthesia) and 
prolonged treatment time (>100 min under general an-
esthesia) did not contribute to delayed recovery. In the 
present study, mean operation time was so long (131 
min in Group PO) that oral midazolam probably did not 
affect recovery time.
As an administration route for midazolam, the oral 
route is more comfortable than other routes, such as 
intramuscular, intranasal and intrarectal routes. Some 
investigators compared the administration routes of mi-
dazolam. One study compared intramuscular and intra-
nasal administration of midazolam (22). The intramus-
cular route allowed for a better sedation level and less 
movement at the time of venous cannulation than the 
intranasal route. Malinovsky et al. (23) compared 0.2 
mg/kg intranasal, 0.3 mg/kg rectal and 0.5 mg/kg oral 
administration of midazolam and concluded that the 
intranasal route had the most rapid onset of sedation. 
IM, intramuscular premedication; PO, oral premedication
The agitation score was defined as follows: 1, sleeping; 2, awake, 
calm; 3, irritable, crying; 4, inconsolable crying; 5, severe rest-












Table 4. Agitation scores after extubation.
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However, application of the intranasal administration 
route to patients with intellectual disability is difficult 
because of their uncooperative and combative attitude.
Although our results showed the superiority of 0.3 mg 
of oral midazolam, oral administration has two disad-
vantages. First, onset time through the oral route is lon-
ger than that with the intramuscular route. It takes about 
30 min to achieve the maximum sedative effect based 
on the peak effect (6,17). Second, patients with intellec-
tual disability do not always accept orally administered 
medicine. Some patients may refuse to drink a drug so-
lution or spit it out after taking it into their mouth. In our 
hospital, midazolam is mixed with a sweetened syrup 
(24) to make it more palatable. If a patient refuses to 
drink the midazolam solution, the drug is administered 
intramuscularly.
There are some limitations to the present study. First, 
most patients were on regular medication, such as an-
ticonvulsant and anxiolytic drugs, which might affect 
the effectiveness of midazolam. However, it was neither 
possible to omit these drugs before anesthesia, nor to 
implement a study using these drugs, because of the 
variety of drugs and doses received by the patients. 
Second, the main biases of our study are that it was a 
retrospective, uncontrolled and unblinded study with a 
small sample size. We could not implement a random-
ized controlled prospective protocol for this study be-
cause many patients’ parents or caregivers requested 
the oral route of midazolam administration when pro-
viding informed consent, and hence, we could not ran-
domly allocate patients to the two groups. The sample 
size of this study was small because many patients were 
excluded due to insufficient information on outcome 
variables. Moreover, the administration route was not 
blinded to the evaluator. Therefore, the possibility of 
selection and observer bias exists in the present study. 
Third, the study patients had different pathologies and 
degrees of intellectual disability. Asahi et al. (16) dem-
onstrated that autistic patients require more propofol 
compared with intellectually impaired patients during 
dental treatment under intravenous general anesthesia. 
Since the difference in the pathology and degree of in-
tellectual disability was not considered in the present 
study, further study on the influence of these different 
pathologies on the required dose of midazolam should 
be explored. Fourth, because the oral dose of midazolam 
was limited to a maximum of 20 mg, patients weighing 
over 67 kg were excluded from the study. Therefore, we 
cannot provide useful information about the appropriate 
midazolam dose in obese patients.
Conclusions
As premedication for intellectually disabled dental pa-
tients, 0.3 mg/kg of oral midazolam was more effective 
than 0.15 mg/kg of intramuscular midazolam in terms 
of patient cooperation for venous cannulation, without 
resultant prolongation of recovery time. If both oral and 
intramuscular midazolam are acceptable, oral adminis-
tration is recommended due to less resistant behaviors 
by the patient for venous cannulation.
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